Effects of health insurance on racial disparity in osteoporosis medication adherence

Journal of the American Pharmacists Association

Volumn 53, Issue 6, 2013, Pages 626-631

  Yoo, Ji Won ^a,b   Kim, Sulgi ^c   Kim, Sun Jung ^d   Ryu, Woo Sang ^e   Min, Too Jae ^e   Shin, Hyun Phil ^f   Kim, Kyudam ^g   Choi, Jong Bum ^d   Nakagawa, Shunichi ^h  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b AURORA HEALTH CARE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Kyung Hee University Hospital   (South Korea)

^g Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^h Columbia University ^*  (United States)

Author keywords

Health insurance; Older patients; Osteoporosis; Pharmacotherapy; Women's health

Indexed keywords

AGED; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CENTER; HEALTH DISPARITY; HEALTH INSURANCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICARE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ELECTRONIC HEALTH RECORDS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; LONGITUDINAL STUDIES; MEDICARE; MEDICATION ADHERENCE; OHIO; OSTEOPOROSIS; UNITED STATES;

EID: 84890519808     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2013.13061     Document Type: Article

References (35)

1. National Institute of Health. Osteoporosis prevention, diagnosis, and therapy. www.consensus.nih.gov/2000/2000osteoporosis111html.htm. Accessed May 19, 2013.
2. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis: 2009. www.nof.org/sites/default/NOF- clinicianguide2009-v7.pdf. Accessed May 19, 2013.
3. Olenginski TP, Antohe JL, Sunderlin E, Harrington TM. Appraising osteoporosis care gaps. Rheumatol Int. 2012;32(11):3619-24.
4. Siris ES, Harris ST, Rosen CJ. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22.
5. Johnson JF, Koenigsfeld C, Hughell L, et al. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc. 2008;48(3):379-87.
6. Institute of Medicine. Unequal treatment: what healthcare providers need to know about racial and ethnic disparities in healthcare. In: Shaping the future for health. www.iom.edu/Object.File/Master/4/175/0.pdf. Accessed May 19, 2013.
7. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt). 2006;15(6):709-19.
8. Curtis JR, McClure LA, Delzell E, et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med. 2009;24(8):956-62.
9. Gourlay ML, Callahan LF, Preisser JS, Sloane PD. Osteoporosis preventive care in white and black women in community family medicine settings. South Med J. 2007;100(7):677-82.
10. Hamrick I, Whetstone LM, Cummings DM. Racial disparity in treatment of osteoporosis after diagnosis. Osteoporos Int. 2006;17(11):1653-8.
11. Gold R, Michael YL, Whitlock EP, et al. Race/ethnicity, socioeconomic status, and lifetime morbidity burden in the Women's Health Initiative: a cross-sectional analysis. J Womens Health (Larchmt). 2006;15(10):1161-73.
12. Whitson HE, Hastings SN, Landerman LR, et al. Black-white disparity in disability: the role of medical conditions. J Am Geriatr Soc. 2011;59(5):844-50.
13. Kim HS. Older women's health and its impact of wealth. J Women Aging. 2006;18(1):75-91.
14. Kirby JB, Taliaferro G, Zuvekas SH. Explaining racial and ethnic disparities in health care. Med Care. 2006;44(5 suppl):I64-72.
15. Hargraves JL, Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Serv Res. 2003;38(3):809-29.
16. Sabik LM, Dahman BA. Trends in care for uninsured adults and disparities in care by insurance status. Med Care Res Rev. 2012;69(2):215-30.
17. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-9.
18. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medication. Arch Intern Med. 2005;165(20):2414-9.
19. Hansen KE, Swenson ED, Baltz B, et al. Adherence to alendronate in male veterans. Osteoporos Int. 2008;19(3):349-56.
20. Cadarette SM, Burden AM. Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin in Rheumatol. 2010;22(4):397-403.
21. Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58(4):650-7.
22. Jachna CM, Shireman TI, Whittle J, et al. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc. 2005;53(8):1275-81.
23. Colón-Emeric C, Lyles KW, Levine DA, et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int. 2007;18(4):553-9.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2005.
25. Alegria M, Lin J, Chen CN, et al. The impact of insurance coverage in diminishing racial and ethnic disparities in behavioral health services. Health Serv Res. 2012;47(3 pt 2):1322-44.
26. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157-64.
27. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-6.
28. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-8.
29. Library of Congress. HR 3590: Patient Protection and Affordable Care Act. www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf. Accessed May 19, 2013.
30. Davisson L, Warden M, Manivannan S, et al. Osteoporosis screening: factors associated with bone mineral density testing of older women. J Womens Health (Larchmt). 2009;18(7):989-94.
31. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
32. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am. 2012;41(3):487-506.
33. Zafran N, Liss Z, Peled R, et al. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int. 2005;16(11):1375-83.
34. Meadows ES, Mitchell BD, Bolge SC, et al. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health. 2012;12:1.
35. Food and Drug Administration. Generic Fosamax approved. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116854.htm. Accessed May 19, 2013.